2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Multiple Sclerosis, Primary Progressive: new trials by email Literature Review of Multiple Sclerosis, Primary Progressive trials Research Report on Multiple Sclerosis, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Fenebrutinib, Ocrelizumab, Placebo matched to ocrelizumab - Multiple Sclerosis, Primary Progressive | Phase 3 | Active not recruiting | Hoffmann-La Roche | 985 | 2020-10-26 | 2026-09-17 |
| A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis Ocrelizumab, Placebo - Multiple Sclerosis, Primary Progressive | Phase 3 | Active not recruiting | Hoffmann-La Roche | 1013 | 2019-08-12 | 2026-02-23 |
Multiple Sclerosis, Chronic Progressive (2)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Chronic Disease (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Disease Attributes (2) · Immune System Diseases (2) · Multiple Sclerosis (2) · Nervous System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
ocrelizumab (2) · fenebrutinib (1)
Australia (2) · Bulgaria (2) · Canada (2) · Colombia (2) · France (2) · Italy (2) · Mexico (2) · Poland (2) · Portugal (2) · Russia (2) · Spain (2) · Ukraine (2) · United Kingdom (2) · United States (2) · Argentina (1)
2018 (1), 2019 (1), 2023 (1)